Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer * Stage IIIB/IV or recurrent non-small cell lung cancer which is not amenable to curative intent therapy * Patients must have one of the following: * NSCLC which harbors EGFR exon 19 deletion or L858R mutation. This subset of patients must be TKI naive; OR * NSCLC which harbors an EGFR T790M mutation that was acquired following progression on erlotinib, gefitinib or afatinib. This subset of patients must have not received prior third generation TKI * NOTE: EGFR mutation must be documented by a Clinical Laboratory Improvement Amendments (CLIA) certified test * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Candidate for local consolidation therapy to at least one site of disease * Signed and dated written informed consent prior to admission to the study in accordance with International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)-Good Clinical Practice (GCP) guidelines and to the local legislation * Ability to take pills by mouth * Females of childbearing potential: * Must not be breast feeding * Must have a negative serum or urine pregnancy test * Must agree to use adequate contraception for a minimum of two weeks prior to receiving study medication until 3 months after discontinuation of the study medication * NOTE: A…